Mesenchymal Stem Cell-Derived Exosomes for Immune-Mediated Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-mediated inflammatory diseases lack effective, immunomodulatory therapies that can safely and efficiently modulate immune responses, particularly in clinical settings, where exosomes derived from mesenchymal stem cells (MSCs) have shown promise but require standardized production methods and characterization for therapeutic use.
Innovation Solution
Isolation and characterization of exosomes derived from human adipose mesenchymal stem cells (MSCs) with specific molecular weight, diameter, and protein content, including thrombospondin-1, and low TGF-β levels, using methods such as filtration and centrifugation, which are scalable and safe for clinical application, and combining these exosomes with TGF-β inhibitors for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If exosomes are isolated using conventional ultracentrifugation methods, then exosome samples can be obtained for research purposes, but the isolation protocols lack standardization and are not suitable for clinical-grade production
Solution Approach 1:
The patent changes the isolation parameter from ultracentrifugation to size-based filtration using membranes with specific molecular weight cut-offs (3 kDa or 100 kDa). This parameter change enables standardized, scalable isolation protocols that are suitable for clinical-grade production while maintaining exosome integrity and immunomodulatory function.
2Reliability
If MSC transplantation is used to treat immune-mediated diseases, then therapeutic effects are achieved through paracrine mechanisms, but transferred cells may die or not fully home into the damaged tissue
Solution Approach 1:
The patent extracts the therapeutic paracrine factors from MSCs by isolating exosomes secreted by these cells. This extraction approach delivers the beneficial immunomodulatory components without the drawbacks of whole cell transplantation, such as cell death and poor homing, while maintaining the therapeutic effects through standardized exosome administration.
3Reliability
If exosomes with high TGF-β levels are used for immunomodulation, then some immunosuppressive effects are achieved, but this may not provide sufficient inhibition of T cell differentiation and activation
Solution Approach 1:
The patent changes the biochemical parameter of exosomes by selecting and characterizing those with low TGF-β levels. This parameter change reveals a novel immunomodulatory mechanism that achieves superior inhibition of T cell differentiation, activation, and proliferation compared to conventional high TGF-β exosomes, providing enhanced therapeutic efficacy for immune-mediated diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The characterized exosomes demonstrate immunomodulatory effects by inhibiting T cell differentiation, activation, and proliferation, providing a therapeutic option for immune-mediated inflammatory diseases with controlled dosage and reduced side effects, as evidenced by in vitro studies.
Implementation Method 1
filtering a cell-free MSC-conditioned medium using a 3 kDa cut-off membrane and recovering the retentate
Implementation Method 2
centrifuging a cell-free MSC-conditioned medium at a speed sufficient to precipitate exosomes and recovering the pellet
Data Source
AI summary
The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.